<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112237</url>
  </required_header>
  <id_info>
    <org_study_id>TN-201-0003</org_study_id>
    <nct_id>NCT05112237</nct_id>
  </id_info>
  <brief_title>Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy</brief_title>
  <acronym>MyCLIMB</acronym>
  <official_title>A Prospective and Retrospective Registry and Biomarker Study to Evaluate the Natural History of Pediatric Patients With Cardiomyopathy Due to MYBPC3 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tenaya Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tenaya Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect information on patients with cardiomyopathy (CM)&#xD;
      due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness,&#xD;
      risk factors for this disease, and the quality of life (QoL). This study will also collect&#xD;
      information on treatments, procedures and outcome in infants and children up to 18 yrs who&#xD;
      have this mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement</measure>
    <time_frame>5 years for prospective group, n/a for retrospective group</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Retrospective</arm_group_label>
    <description>All patients who meet the eligibility criteria will be eligible for retrospective chart review with no maximum number of patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective</arm_group_label>
    <description>100 patients meeting the eligibility criteria will be followed for 5 years, in addition to a retrospective chart review. Assessments will be completed as part of a participant's regular schedule of physician visits, no additional visits will be required. Aside from a simple annual blood draw, assessments are non-invasive, including a Quality of Life questionnaire.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under the age of 18 years (at enrollment) with cardiomyopathy (CM) and pathogenic&#xD;
        or likely pathogenic MYBPC3 genetic mutation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Retrospective&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Data is available for patient &lt;18 years of age.&#xD;
&#xD;
          -  Documented results of genotyping showing the presence of at least one pathogenic or&#xD;
             likely pathogenic MYBPC3 mutation (heterozygous, homozygous, or compound&#xD;
             heterozygous).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient received cardiac transplantation or died &gt;10 years before study initiation.&#xD;
&#xD;
        Prospective&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 at entry into the prospective study.&#xD;
&#xD;
          -  Documented results of genotyping identifying at least one pathogenic or likely&#xD;
             pathogenic MYBPC3 mutation (heterozygous, homozygous, or compound heterozygous).&#xD;
&#xD;
          -  Infants who are homozygous or compound heterozygous for the known pathogenic&#xD;
             truncating MYBPC3 mutations are eligible.&#xD;
&#xD;
          -  Heterozygous participants must have a diagnosis of Cardiomyopathy (CM: HCM, DCM, RCM,&#xD;
             mixed CM, or LVNC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent participation in an interventional clinical trial unless approved by the&#xD;
             sponsor.&#xD;
&#xD;
          -  Severe noncardiac disease is anticipated to significantly reduce life expectancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Robertson, MD</last_name>
    <phone>6508256990</phone>
    <email>lrobertson@tenayathera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LaTanya Tomlinson</last_name>
    <email>ltomlinson@tenayathera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DDC Clinic Center for Special Needs Children</name>
      <address>
        <city>Middlefield</city>
        <state>Ohio</state>
        <zip>44062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic Cardiomyopathy</keyword>
  <keyword>Pediatric</keyword>
  <keyword>MYBPC3</keyword>
  <keyword>Hypertrophic Cardiomyopathy (HCM)</keyword>
  <keyword>Dilated Cardiomyopathy</keyword>
  <keyword>Restrictive Cardiomyopathy</keyword>
  <keyword>Non-Compaction cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

